Literature Analysis of Adverse Drug Reactions/Events Induced by Thiamazole

Abstract

Abstract: Objective To investigate and analyze the literatures on clinical application and ADR/ADE induced by thiamazole, so as to provide reference for its rational use in clinic. Methods The literatures for the clinical application and ADR/ADE of thiamazole were retrieved in the databases of Pubmed, Embase and CNKI, Wangfang data. The related literatures were screened out and analyzed by evidence-based medicine method and bibliometric statistical method. Results 117 available literatures were retireved; 449 adverse drug reaction cases were collected. Female patients were 4.80 times that of male patients, the most of patients were 15 to 44 years old, the serious adverse drug reactions (events) were mainly blood system damage and hepatobiliary disorders, accountiong for 48.12% and 22.26% respectively. Conclusion We should reinforce the clinical application monitoring of thiamazole, standardize and improve the drug manual, promte the rational application of drug.

Key words: thiamazole/methimazole, clinical application, agranulocytosis, liver damage, adverse drug reaction/event

CLC Number:

R994.11

PENG Lili, LIU Wei, TANG Ren, LI Lan, FAN Yan. Literature Analysis of Adverse Drug Reactions/Events Induced by Thiamazole[J]. Chinese Journal of Pharmacovigilance, 2018, 15(7): 404-410.

References

[1] 葛均波,徐永健. 内科学[M]. 8版. 北京:人民卫生出版社,2013:416-418,685-690.
[2] 卫生部合理用药专家委员会. 中国医师药师临床用药指南[M]. 2版. 重庆:重庆出版集团重庆出版社, 2014:975-977.
[3] 王晓虹,马建丽, 罗艳, 等.甲巯咪唑的严重不良反应及处理对策[J]. 实用药物与临床, 2014, 17(12):1604-1606.
[4] 杨宝峰, 苏定冯. 药理学[M]. 8版. 北京:人民卫生出版社,2013: 345.
[5] 王晓虹, 马建丽, 罗艳, 等. 甲巯咪唑的严重不良反应及处理对策[J]. 实用药物与临床, 2014, 17(12):1604-1609.
[6] 王吉耀. 内科学[M]. 北京:人民卫生出版社, 2002:886.
[7] 陶娌娜, 曲晓宇, 张四喜, 等.甲巯咪唑致重度粒细胞缺乏1例[J]. 中国药物应用与监测, 2016, 13(4):258-260.
[8] 王贵银. 甲巯咪唑引起粒细胞缺乏症60例分析[J]. 药物流行病学杂志, 2001, 10(2):67-68.
[9] 冉广宇, 陈惠玲. 甲巯咪唑致粒细胞减少1例药学监护[J]. 世界最新医学信息文摘:连续型电子期刊, 2015, 15(33):129-130.
[10] 杨凤娥, 傅丹晖, 杨婷, 等.甲硫咪唑致粒细胞缺乏症21例临床分析[J]. 福建医科大学学报, 2003, 37(4):360-360.
[11] 陈三军, 陈文准. 他巴唑引起粒细胞缺乏症1例报告[J]. 江西医学院学报, 1996, 36(1):12.
[12] Emiliano A B, Governale L, Parks M, et al.Shifts in pro-pylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008[J]. J Clin Endocrinol Metab, 2010, 95(5):2227-2233.
[13] Yang J, Zhong J, Zhou L Z, et al.Sudden onset agranulocytosis and hepatotoxicity after taking methimazole[J]. Intern Med, 2012, 51(16):2189-2192.
[14] Pisciotta A V.Immune and toxic mechanisms in drug-induced agranulocytosis[J]. Semin Hematol, 1973, 10(4):279-310.
[15] Takata K, Kubota S, Fukata S, et al.Methimazole -induced agranulocytosis in patients with Graves' disease is more frequent with aninitial dose of 30 mg daily than with 15 mg daily[J]. Thyroid, 2009, 19(6): 559-563.
[16] Cooper D S, Goldminz D, Levin A A, et al.Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose[J]. Ann Intern Med, 1983, 98(1): 26-29.
[17] Honda M.Successful treatment of methimazoleinduced severe aplastic anemia by granulocyte colonystimulating factor, methylp-rednisolone, and cyclosporin[J]. ISRN Endocrinol, 2011,22(8): 732623.
[18] 陈秋红, 陈文灯. 甲巯咪唑片致过敏性紫癜1例[J]. 中国药物警戒, 2016, 13(7):442-442.
[19] 沈明艳, 何一凡, 张金苹, 等. 甲巯咪唑致胆汁淤积性肝损害4例临床分析[J]. 中日友好医院学报, 2012, 26(4):199-201.
[20] 廖戮缪. 甲巯咪唑和丙硫氧嘧啶对肝功能影响的前瞻性研究[D]. 南宁: 广西医科大学,2012:22.
[21] 陈陶,汤杰, 李娟, 等. 甲巯咪唑致混合性肝损害1例[J]. 医药导报, 2014, 33(10):1393-1394.
[22] 葛均波, 徐永健. 内科学[M]. 8版. 北京:人民卫生出版社, 2013:690-691.
[23] 钱红霞, 李新胜, 王荣荣, 等.甲巯咪唑相关性胰岛素自身免疫综合征伴低血糖昏迷一例报告[J].中国糖尿病杂志, 2015, 23(1):83-84.
[24] Nakamura H, Miyauchi A, Miyawaki N, et al.Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan[J]. J Clin Endocrinol Metab,2013, 98(12):4776-4783.
[25] Takata K, Kubota S, Fukata S, et al.Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily[J]. Thyroid 2009, 19(6):559-563.
[26] 国家食品药品监督管理总局.药物警戒快讯(162)[EB/OL]. (2016-12-02)[2018-06-02]. http://www.sda.gov.cn/WS01/CL0389/166984.html.2016-12-02.
[27] 卫生部合理用药专家委员会.中国医师药师临床用药指南[M]. 2版. 重庆:重庆出版集团重庆出版, 2014:975-977.
[28] CFDA-CDR.世界卫生组织提示可能存在甲巯咪唑与横纹肌溶解症相关的信号[EB/OL]. (2016-10-28)[2018-06-02]. http://www.cdr-adr.org.cn/yxaqjs/gj/201610/t20161028_17987.html.
[29] The United States Pharmacopieial Convention.The United States Pharmacopeia:General Chapters[S]. 40th Edition.Rockville:The United States Pharmacopieial Convention, 2017:354-359.
[30] CFDA.总局关于修订甲巯咪唑片说明书的公告(2018年第17号)[EB/OL]. (2018-02-09)[2018-05-29]. http://samr.cfda.gov.cn/WS01/CL1706/224559.html.